- recruitingPHASE1
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
This early-stage study is testing a new cell therapy called MDC-CAR-BCMA001. It aims to find the safest dose for people with certain types of blood cancers, like some lymphomas and multiple myeloma, that have come back or not responded to other treatments.
Germany - recruitingPHASE2
DALY II USA/ MB-CART2019.1 for DLBCL
This study is testing a new cell therapy called zamtocabtagene autoleucel for different types of lymphoma, including Diffuse Large B-cell Lymphoma (DLBCL), when other treatments haven't worked. It looks at how well it works and if it's safe.
United States · Canada